Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube…
NCT00004064 · AltaRex, Industry · Unknown status
Key facts
| NCT number | NCT00004064 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of the Safety and Efficacy of OVAREX MabB43.13 in Ovarian Cancer Patients With an Elevated Serum CA 125 But Without Other Evidence of Disease |
| Lead sponsor | AltaRex, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Biological |
| Interventions | oregovomab |
| Enrollment | 102 |
| Start date | Nov 1, 1998 |
| First posted | Aug 5, 2004 |
| Last update posted | Nov 6, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: